Sam Lai is a Professor at UNC Eshelman School of Pharmacy, where Sam also serves as the Director of the Pharmacoengineering Program and the E(I) Lab. With a background in Chemical & Biomolecular Engineering, Sam has also founded companies such as Inhalon Biopharma and Mucommune, LLC, where Sam holds the titles of Founder, CSO, and CEO respectively. Additionally, Sam has experience as an Assistant Director at the Eshelman Institute of Innovation and has had research roles at Johns Hopkins University, focusing on drug delivery, biotechnology, mucus, infectious diseases, and nanotechnology.
This person is not in any offices